Within the next two weeks we should get some statements regarding the future direction/status of Cart T cell Partnership,EAP and Cardiac Partner. Hopefully we will learn more about Fresenius sales projections. We shave a lot to look forwards too.
ping - I can see why you would say that, but we all know the second quarter is going to be more like the first quarter. Going forward Dr. Chan said during the second half CTSO sales would be back on track.
My interpretation on the shelf offering is that the "potential" cardiac partner, for whatever reason, decided not to pony up as much cash ( or agree to terms) as what CTSO may have wanted, leaving the company to file the shelf offering to finance future trials.
As for the future, I think the arrangement with Fresenius will be a catalyst for CTSO.
What are your expectations that have tempered your future outlook?
As always, thanks for your input.
A $40 pps would mean a little more than a billion $ market cap. We could get that on some positive news. Without having to wait for sales.
mr_p, thanks for your garnishing and sharing of facts. While inclusion of CTSO into the Russell micro-cap gives the company credibility as a viable corporate entity, it doesn't look like inclusion by itself will not do much for demand of the stock to to move the pps.
While the dollar amount is nominal, the fact that the doctor recognized using the filter as a viable therapy is extremely significant!
10. A potential Cardiac partner is evaluating the filter. Can you share what indication/application the filter is being evaluated for? Has the potential partner committed to time when their analysis will be complete? Can you share what may be unique about this particular partnership agreement?
Correct, they looked at the past two quarters and inferred that it is a trend. Not mentioned in the opinion was that the CTSO has increased production by adding a second shift.
The market Cap for CTSO is now about $180MM. It has not been that low for a long time. I picked up some more shares for my grand kids.
This is a study that can be done very rapidly and is the reason why we have nearly 300 -- actually more than 300 intraoperative cardiac surgery treatments already in Germany and in Austria.
How many of those 300 were neutral or negative?
With a Chronologically Orientation for Pessimism, Misunderstood and Buffoonery....
From the transcript Dr. Chan describes the REFRESH trial design for the cardiac bypass surgery - "....this reduction in free hemoglobin trial is a 20-patient multicenter feasibility study evaluating the safety of CytoSorb when used intraoperatively in a bypass circuit in a heart-lung machine during complex cardiac surgery. And the goal here again is to try to reduce levels of free hemoglobin and other inflammatory mediators that if left unabated can cause postoperative complications.The trial is on target to commence midyear and is expected to be completed before year end. It's very important to note that this is a much different trial than a critical care trial or an ICU trial. The only intervention is using CytoSorb in a bypass circuit during the three to five hours of the cardiac surgery. Its one and done. After the surgery all that is required of the study nurse and the clinical team just take blood -- blood draws every day and to evaluate the patient clinically, until the patient leaves the intensive care unit. This is a study that can be done very rapidly and is the reason why we have nearly 300 -- actually more than 300 intraoperative cardiac surgery treatments already in Germany and in Austria."
We could have some more data by year end.
From the transcript; Dr. Chan is giving a breakdown on status on the partnerships and talks of appling for Canadian approval, "We’ve also met the requirements to add Canadian registration to our ISO 13485 certification and this will allow CytoSorb to be registered in Canada once all Health Canada requirements have been met." That is the first I have heard that actionable steps have been taken for Canadian approval.
I agree - First thing this morning the quarterly financial report, I believe management is saying "let's just get the information out and put the issue behind us so that we are not preoccupied with it as we roll out for the future."